US-based Catalent Pharma Solutions is set to expand its biologics packaging plant in Bloomington, Indiana, with a $14m investment.
The investment will be used to construct the 15,000ft2 facility infrastructure, featuring five new packaging suites and a new quality control laboratory.
Construction is expected to complete in February.
Following construction, the company will focus on installation and commissioning of new equipment at the facility, including a semi-automated and fully automated top-loading cartoner.
The company will install an accessorised combination syringe assembly machine, an automated auto-injector assembly machine, and two semi-automatic visual inspection machines.
Catalent Biologics Drug Product business vice-president and general manager Cory Lewis said: “This significant investment is due in a large part to Catalent’s extensive expertise in helping customers successfully navigate all stages of development and gain commercial approval for their drug products.
“The packaging expansion will further enhance our comprehensive end-to-end offering for clinical and commercial customers, complementing the services that Catalent Biologics provides, including cell line development, biologics analytical, biomanufacturing, antibody-drug conjugate development, drug product fill/finish, and clinical supply services.”
The company expects that the expansion will offer automated packaging solutions to its customers.
The auto-injector and accessorised syringe assembly machines at the facility are set to offer improved patient compliance and safety for healthcare providers who administer injections.
The facility expansion is expected to create 36 new jobs at the site, which was acquired by Catalent last year.